MARKET

ALVO

ALVO

Alvotech
NASDAQ
3.670
+0.120
+3.38%
Pre Market: 3.670 0 0.00% 06:20 05/14 EDT
OPEN
3.510
PREV CLOSE
3.550
HIGH
3.730
LOW
3.440
VOLUME
100
TURNOVER
0
52 WEEK HIGH
11.85
52 WEEK LOW
3.030
MARKET CAP
1.15B
P/E (TTM)
38.07
1D
5D
1M
3M
1Y
5Y
1D
Alvotech Clears Key FDA Inspection at Reykjavik Plant, Paving Way for 2026 BLA Resubmissions
TipRanks · 3d ago
Alvotech Completes FDA Surveillance Inspection At Reykjavik Facility, Prepares BLA Resubmissions
NASDAQ · 3d ago
Alvotech shares rise as FDA completes Reykjavik facility inspection
Seeking Alpha · 3d ago
Weekly Report: what happened at ALVO last week (0504-0508)?
Weekly Report · 3d ago
Alvotech announces cGMP surveillance inspection of Reykjavik facility
TipRanks · 3d ago
Alvotech says FDA completes inspection of Reykjavik manufacturing plant
PUBT · 3d ago
ALVOTECH SA - EXPECTS FDA APPROVAL FOR RELEVANT BLAS IN 2026
Reuters · 3d ago
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
Barchart · 3d ago
More
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Webull offers Alvotech SA stock information, including NASDAQ: ALVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALVO stock methods without spending real money on the virtual paper trading platform.